Fabio Centola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabio Centola has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Mara Rossi
Analytical Excellence and Program Management Merck Serono S.P.A Rome Italy
3 shared publicationsIvano Eberini
Dipartimento di Scienze Farmacologiche e Biomolecolari & Data Science Research Center (DSRC), Università degli Studi di Milano, Milan, Italy
2 shared publicationsOmar Ben Mariem
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy
2 shared publicationsSimona Saporiti
Analytical Excellence and Program Management Merck Serono S.P.A Rome Italy
2 shared publications- Simona Saporiti
Analytical Excellence and Program Management, Merck Serono S.p.A., Rome, Italy
2 shared publications Uliano Guerrini
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by MDPI AG in Journal of Pharmaceutical and BioTech Industry
- Vol. 3 (3) , 21
Physicochemical and Functional Comparison Between the Cetuximab Biosimilars Cetuxa® and Lupitux® and Cetuximab Originator Erbitux®
ENZ-124, the first approved cetuximab biosimilar by Indian health authorities, was developed using the Chinese hamster ovary cell line, whereas the SP2/0 cell line was used for developing cetuximab originator (Erbitux®). Hence, this assessment aimed to evaluate the physiochemical, structural, and biological characterization of four batches each of Cetuxa®, Lupitux® and cetuximab originator. Analytical methods like peptide mapping (liquid chromatography–tandem mass spectrometry [LC-MS/MS]), glycan mapping (liquid chromatography–fluorescence detection), isoform analysis (hydrophobic interaction chromatography [HIC]-high-performance liquid chromatography), charge variant analysis (capillary electrophoresis coupled with mass spectrometry), FcγRIIIa binding assays, cell-based antibody-dependent cell-mediated cytotoxicity (ADCC) measurement, and host cell protein analysis (LC-MS/MS) were utilized for analysis. Variations in physicochemical and biological attributes were observed between cetuximab originator and its biosimilars. HIC analysis revealed C-terminal heterogeneity and increased hydrophobicity in biosimilars, that with the different N-glycan profile affected charge distribution. Charge variant analysis indicated a more acidic profile for the biosimilars. The biosimilars showed higher oxidation levels and misincorporation. The biosimilars also showed an enhanced FcγRIIIa binding affinity and in vitro ADCC activation compared with cetuximab originator. The study outcomes highlight the ability to differentiate cetuximab originator from its biosimilars Cetuxa® and Lupitux® based on the observed physicochemical and biological differences.
- 10 September 2026
- Published by MDPI AG in Journal of Pharmaceutical and BioTech Industry
- Vol. 3 (3) , 21
Open AccessPhysicochemical and Functional Comparison Between the Cetuximab Biosimilars Cetuxa® and Lupitux® and Cetuximab Originator Erbitux®
ENZ-124, the first approved cetuximab biosimilar by Indian health authorities, was developed using the Chinese hamster ovary cell line, whereas the SP2/0 cell line was used for developing cetuximab originator (Erbitux®). Hence, this assessment aimed to evaluate the physiochemical, structural, and biological characterization of four batches each of Cetuxa®, Lupitux® and cetuximab originator. Analytical methods like peptide mapping (liquid chromatography–tandem mass spectrometry [LC-MS/MS]), glycan mapping (liquid chromatography–fluorescence detection), isoform analysis (hydrophobic interaction chromatography [HIC]-high-performance liquid chromatography), charge variant analysis (capillary electrophoresis coupled with mass spectrometry), FcγRIIIa binding assays, cell-based antibody-dependent cell-mediated cytotoxicity (ADCC) measurement, and host cell protein analysis (LC-MS/MS) were utilized for analysis. Variations in physicochemical and biological attributes were observed between cetuximab originator and its biosimilars. HIC analysis revealed C-terminal heterogeneity and increased hydrophobicity in biosimilars, that with the different N-glycan profile affected charge distribution. Charge variant analysis indicated a more acidic profile for the biosimilars. The biosimilars showed higher oxidation levels and misincorporation. The biosimilars also showed an enhanced FcγRIIIa binding affinity and in vitro ADCC activation compared with cetuximab originator. The study outcomes highlight the ability to differentiate cetuximab originator from its biosimilars Cetuxa® and Lupitux® based on the observed physicochemical and biological differences.
- Open Access
- 31 October 2025
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 94 (3) , 838-852
In Silico Structural Analysis of Human β‐Glucuronidase for Antibody–Drug Conjugates Optimization
Human β‐glucuronidase (HGUSB), a key lysosomal glycosyl hydrolase for the degradation pathway of glycosaminoglycans (GAGs), plays a crucial role in cell proliferation and inflammation, making it a promising target for novel therapeutic strategies including antibody‐drug conjugates (ADCs) with β‐glucuronic linkers. In this study, molecular docking and molecular dynamics (MD) simulations were performed to investigate the conformational stability of HGUSB in complex with different ligands, including substrates, inhibitors, and β‐glucuronic linkers. Our rationale approach includes the evaluation of commercial substrates and a known inhibitor with different binding stoichiometries to identify the most favorable configuration and the most stable conformation of the enzyme. Based on the binding mechanism of HGUSB to these well‐known ligands, the interaction with commercial linkers was evaluated, providing a structural determination of the recognition mechanism between the enzyme and ADCs. MD simulations on HGUSB::Linker complexes revealed that the maleimide‐containing hydrophilic β‐glucuronide, exhibited the most stable binding making it the best fitting linker among those analyzed in this study. Overall, this study identifies the optimal binding configuration of the HGUSB enzyme for investigating small molecule interactions and, despite the endogenous homotetrameric assembly, justifies the use of a simplified monomeric model for the study of larger macromolecular complexes, like linker analysis, ensuring an efficient and accurate computational approach. These findings lay the groundwork for a rationale optimization of β‐glucuronic linker‐based ADCs, offering new perspectives for targeted cancer therapies.
- 31 October 2025
- Published by Wiley in Proteins: Structure, Function, and Bioinformatics
- Vol. 94 (3) , 838-852
Open AccessIn Silico Structural Analysis of Human β‐Glucuronidase for Antibody–Drug Conjugates Optimization
Human β‐glucuronidase (HGUSB), a key lysosomal glycosyl hydrolase for the degradation pathway of glycosaminoglycans (GAGs), plays a crucial role in cell proliferation and inflammation, making it a promising target for novel therapeutic strategies including antibody‐drug conjugates (ADCs) with β‐glucuronic linkers. In this study, molecular docking and molecular dynamics (MD) simulations were performed to investigate the conformational stability of HGUSB in complex with different ligands, including substrates, inhibitors, and β‐glucuronic linkers. Our rationale approach includes the evaluation of commercial substrates and a known inhibitor with different binding stoichiometries to identify the most favorable configuration and the most stable conformation of the enzyme. Based on the binding mechanism of HGUSB to these well‐known ligands, the interaction with commercial linkers was evaluated, providing a structural determination of the recognition mechanism between the enzyme and ADCs. MD simulations on HGUSB::Linker complexes revealed that the maleimide‐containing hydrophilic β‐glucuronide, exhibited the most stable binding making it the best fitting linker among those analyzed in this study. Overall, this study identifies the optimal binding configuration of the HGUSB enzyme for investigating small molecule interactions and, despite the endogenous homotetrameric assembly, justifies the use of a simplified monomeric model for the study of larger macromolecular complexes, like linker analysis, ensuring an efficient and accurate computational approach. These findings lay the groundwork for a rationale optimization of β‐glucuronic linker‐based ADCs, offering new perspectives for targeted cancer therapies.
- Open Access
- 8 August 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1429600
In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics
Introduction: N-glycosylation is a post-translational modification that is highly important for the development of monoclonal antibodies (mAbs), as it regulates their biological activity, particularly in terms of immune effector functions. While typically added at the Fc level, approximately 15-25% of circulating antibodies exhibit glycosylation in the Fab domains as well. To the best of our knowledge, cetuximab (Erbitux®) is the only therapeutic antibody presenting Fab glycosylation approved world-wide targeting the epidermal growth factor receptor for the treatment of metastatic-colorectal and head and neck cancers. Additionally, it can trigger antibody-dependent cell cytotoxicity (ADCC), a response that typically is influenced by N-glycosylation at Fc level. However, the role of Fab glycosylation in cetuximab remains poorly understood. Hence, this study aims to investigate the structural role of Fab glycosylation on the conformational behavior of cetuximab.Methods: The study was performed in silico via accelerated molecular dynamics simulations. The commercial cetuximab was compared to its form without Fab glycosylation and structural descriptors were evaluated to establish conformational differences.Results: The results clearly show a correlation between the Fab glycosylation and structural descriptors that may modulate the conformational freedom of the antibody, potentially affecting Fc effector functions, and suggesting a negative role of Fab glycosylation on the interaction with FcγRIIIa.Conclusion: Fab glycosylation of cetuximab is the most critical challenge for biosimilar development, but the differences highlighted in this work with respect to its aglycosylated form can improve the knowledge and represent also a great opportunity to develop novel strategies of biotherapeutics.
- 8 August 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1429600
Open AccessIn silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics
Introduction: N-glycosylation is a post-translational modification that is highly important for the development of monoclonal antibodies (mAbs), as it regulates their biological activity, particularly in terms of immune effector functions. While typically added at the Fc level, approximately 15-25% of circulating antibodies exhibit glycosylation in the Fab domains as well. To the best of our knowledge, cetuximab (Erbitux®) is the only therapeutic antibody presenting Fab glycosylation approved world-wide targeting the epidermal growth factor receptor for the treatment of metastatic-colorectal and head and neck cancers. Additionally, it can trigger antibody-dependent cell cytotoxicity (ADCC), a response that typically is influenced by N-glycosylation at Fc level. However, the role of Fab glycosylation in cetuximab remains poorly understood. Hence, this study aims to investigate the structural role of Fab glycosylation on the conformational behavior of cetuximab.Methods: The study was performed in silico via accelerated molecular dynamics simulations. The commercial cetuximab was compared to its form without Fab glycosylation and structural descriptors were evaluated to establish conformational differences.Results: The results clearly show a correlation between the Fab glycosylation and structural descriptors that may modulate the conformational freedom of the antibody, potentially affecting Fc effector functions, and suggesting a negative role of Fab glycosylation on the interaction with FcγRIIIa.Conclusion: Fab glycosylation of cetuximab is the most critical challenge for biosimilar development, but the differences highlighted in this work with respect to its aglycosylated form can improve the knowledge and represent also a great opportunity to develop novel strategies of biotherapeutics.
- Open Access
- 3 March 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-10
Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility
N-glycosylation plays a key role in modulating the bioactivity of monoclonal antibodies (mAbs), as well as the light chain (LC) isotype can influence their physicochemical properties. However, investigating the impact of such features on mAbs conformational behavior is a big challenge, due to the very high flexibility of these biomolecules. In this work we investigate, by accelerated molecular dynamics (aMD), the conformational behavior of two commercial immunoglobulins G1 (IgG1), representative of κ and λ LCs antibodies, in both their fucosylated and afucosylated forms. Our results show, through the identification of a stable conformation, how the combination of fucosylation and LC isotype modulates the hinge behavior, the Fc conformation and the position of the glycan chains, all factors potentially affecting the binding to the FcγRs. This work also represents a technological enhancement in the conformational exploration of mAbs, making aMD a suitable approach to clarify experimental results.
- 3 March 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-10
Open AccessEffect of Fc core fucosylation and light chain isotype on IgG1 flexibility
N-glycosylation plays a key role in modulating the bioactivity of monoclonal antibodies (mAbs), as well as the light chain (LC) isotype can influence their physicochemical properties. However, investigating the impact of such features on mAbs conformational behavior is a big challenge, due to the very high flexibility of these biomolecules. In this work we investigate, by accelerated molecular dynamics (aMD), the conformational behavior of two commercial immunoglobulins G1 (IgG1), representative of κ and λ LCs antibodies, in both their fucosylated and afucosylated forms. Our results show, through the identification of a stable conformation, how the combination of fucosylation and LC isotype modulates the hinge behavior, the Fc conformation and the position of the glycan chains, all factors potentially affecting the binding to the FcγRs. This work also represents a technological enhancement in the conformational exploration of mAbs, making aMD a suitable approach to clarify experimental results.